Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
Wenying YangJianhua MaTianpei HongMing LiuHeng MiaoYongde PengChangjiang WangXiangjin XuTao YangAnne Møller NielsenLili PanWeihong LiuWeigang ZhaoPublished in: Diabetes, obesity & metabolism (2019)
The efficacy and safety of IDegAsp in Chinese patients with T2D was demonstrated, confirming results from international trials.